Tag

Pfizer

11 stories

Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction

Etavopivat cut vaso-occlusive crisis rates by 27% in a 385-patient phase 3 trial, and Novo Nordisk is now targeting an FDA submission in the second half of…

FDA 2 days ago

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3

Merck's MK-2010 posted a 55% unconfirmed overall response rate among 11 previously untreated PD-L1-positive non-small cell lung cancer patients, the first…

Deals 2 days ago

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record

Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA.

Deals 3 days ago

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018

Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…

Deals 4 days ago

Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total

Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…

FDA Apr 13, 2026

Darovasertib Hits 6.9-Month PFS Goal, Ideaya Plans H2 FDA Filing

Darovasertib cleared its primary endpoint in a phase 2/3 trial in metastatic uveal melanoma, posting median progression-free survival of 6.9 months against…

FDA Apr 7, 2026

TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars

White House added Humira to TrumpRx at $950/month, the same site that already lists cheaper Pfizer and Amgen biosimilars.

FDA Apr 7, 2026

Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor

Sanofi's lunsekimig cleared asthma and nasal polyp trials but failed its eczema Phase 2, leaving Dupixent without a clear successor as its patent cliff nears.

FDA Apr 5, 2026

Lipocine's PPD Drug Fails Phase 3, Stock Craters 77%

Lipocine's oral brexanolone failed Phase 3 for postpartum depression, wiping 77% off its stock. The pill version of Zulresso didn't work.

FDA Apr 5, 2026

Pfizer Scraps COVID Vaccine Trial; 80% of Recruits Failed Screening

Pfizer and BioNTech shut down their 25,000–30,000-person COVID trial after 80%+ of recruits failed screening, leaving FDA-required approval data ungenerated.

FDA Apr 5, 2026

Trump's 100% Pharma Tariff: Who Pays, Who Gets Out

Trump's 100% tariff on branded pharma imports creates a hard deadline: cut MFN pricing deals and reshore, or face full tariffs by 2030.